Morphic Holding Inc. (MORF)’s Financial Results Comparing With Sutro Biopharma Inc. (NASDAQ:STRO)

Morphic Holding Inc. (NASDAQ:MORF) and Sutro Biopharma Inc. (NASDAQ:STRO) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Morphic Holding Inc. 22 81.89 N/A -0.81 0.00
Sutro Biopharma Inc. 11 5.37 N/A -1.66 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Morphic Holding Inc. and Sutro Biopharma Inc.


Table 2 provides Morphic Holding Inc. and Sutro Biopharma Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Morphic Holding Inc. 0.00% 0% 0%
Sutro Biopharma Inc. 0.00% 0% 0%


The current Quick Ratio of Morphic Holding Inc. is 4.6 while its Current Ratio is 4.6. Meanwhile, Sutro Biopharma Inc. has a Current Ratio of 5.7 while its Quick Ratio is 5.7. Sutro Biopharma Inc. is better positioned to pay off its short-term and long-term debts than Morphic Holding Inc.

Insider & Institutional Ownership

Roughly 49.9% of Morphic Holding Inc. shares are held by institutional investors while 73.1% of Sutro Biopharma Inc. are owned by institutional investors. About 26.4% of Morphic Holding Inc.’s share are held by insiders. Comparatively, insiders own roughly 21.23% of Sutro Biopharma Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Morphic Holding Inc. 9.03% -2.8% 0% 0% 0% 25.44%
Sutro Biopharma Inc. 1.9% -4.09% 13.27% 5.52% 0% 24.94%

For the past year Morphic Holding Inc.’s stock price has bigger growth than Sutro Biopharma Inc.


Morphic Holding Inc. beats Sutro Biopharma Inc. on 4 of the 5 factors.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.